A targeted drug approach to help Alzheimer's patients by blocking cGAS
Official title: Human CGAS inhibitors to treat neurodegeneration in Alzheimer's disease
Funded at Aeton Therapeutics, INC. · NIH-11323824 · Data updated 2026-11-12
Researchers are developing a brain-penetrant inhibitor of cGAS to reduce neuroinflammation and memory problems in people with Alzheimer's disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aeton Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Burlingame, United States) |
| Project start | September 17, 2026 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $932,681 |
| NIH project number | 1R44AG099654-01 |
| Project ID | NIH-11323824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with Alzheimer's disease or related cognitive impairment who are candidates for disease-modifying therapies and can participate in early-phase research.
✕Less likely to help
Patients with advanced dementia or comorbidities preventing trial participation may not benefit from this specific program.
What this research studies
This project focuses on a small molecule that blocks cGAS, a driver of brain inflammation, with the aim of slowing memory loss in Alzheimer's patients. The work emphasizes low nanomolar potency and aims to demonstrate potential cognitive benefits in models and early studies. By targeting neuroinflammation linked to tau and inflammatory pathways, the researchers hope to slow disease progression and improve daily functioning for patients. The grant supports preclinical development and plans to move toward early human studies if successful.
Why it matters
Potential benefit: If successful, patients with Alzheimer's could experience slowed cognitive decline and better quality of life due to reduced brain inflammation.
How similar studies have gone: Previous efforts targeting inflammatory pathways in AD have shown mixed results, making this a promising but exploratory approach.
Where this research is happening
-
Aeton Therapeutics, INC.
Burlingame, United States Active
Researchers
- Principal investigator: Sinha, Anjana — Aeton Therapeutics, INC.
- Study coordinator: Sinha, Anjana
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.